TLR9 and neoplasm: We hypothesized that the addition of the TLR9 ligand CpG would adjuvant the DC15-NeoAg response; however, even with the addition of CpG, tumours grew progressively in both VHHcont-NeoAg and DC15-NeoAg vaccinated mice (figure 4e).